“Bet hedging” explains the efficacy of many combination cancer therapies
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of “bet hedging,” according to a new study published by Harvard Medical School researchers in Cell on Dec. 14. Read the full story.